20 April 2010- Diabetes mellitus is a lifestyle related chronic metabolic disorder caused due to the failure of body in producing hormone insulin and/or its inability to respond adequately to produced insulin. There are two categories of diabetes- Type 1 diabetes and Type 2 diabetes- with a share of 5-10% and 90-95% respectively of global diagnosed diabetes cases. The treatment of Type 1 diabetes depends basically on diabetic medical supplies, especially diabetes drugs and insulin. Type 2 diabetes is usually treated with intervention in diabetic patient's lifestyle. The World Health Organization (WHO) has estimated the number of diabetics to go beyond 350 million by year 2030. With this large number of global diabetic population, it surely is bound to have impact on diabetes market, especially diabetes drugs market.
The Diabetes drugs market includes Injectables Market like that for Insulin and exenatide; and Oral Drugs Market like those for Metformin, Sulfonylureas, thaizolidinediones, dipeptidyl inhibitors, meglitinides, alpha glucosidase inhibitors, combination medications.
Read more about Anti-Diabetic Drugs
In 2007, the global diabetes market was worth over $25 billion and in 2008, it was worth $27.3 billion. In 2008, the diabetes market was led by insulin analogs that captured 45% of the market followed by glitazones with a share of 22.8%. The largest diabetes market in 2008 was the US with sales of $12.9 billion and a market share of 47.6%. However, the highest growth in sales y-o-y was recorded by many early emerging economies like UAE at 59.7%. In 2008, the prevalence of diabetes in all the leading diabetes market viz. US, Japan, UK, Germany, France, Spain, Italy, Brazil, China and India was 8.5% with Germany having the highest diabetes prevalence rate at 11.8%. However, diabetes is growing at an epidemic proportions that has also led to extensive R&D in its therapy area
Diabetes is prevailing worldwide and rising fast across the globe. Some of the causes for diabetes prevalence include increased life expectancy, inactive lifestyles, and rising incidence of obesity. Most of the developed and developing economies of the world experience all the three factors and thus diabetes prevalence over there is on epidemic measure. The diabetes drugs market of Brazil is continuously showing double digit growth rate. The insulin market of Russia is set to witness significant growth due to its estimated 20 million diabetes patients by 2025. China has already been recognized as diabetic capital of world with the highest number of diabetics. China alone is forecast to have more than 71 million diabetic patients by 2025. India, however is forecast to soon acquire the position of the diabetic capital of world,leaving behind China! Many pharmaceutical companies have already introduced easy-to-use insulin versions to acquire the major diabetes market share in the Indian diabetes drugs market.
Diabetes market has come up as one of the most significant sectors of the pharmaceutical industry. During the period 2010-2025, all the segments of diabetes market will grow at still faster rates. Here are some pointers that indicate towards the shape of the future Diabetes Market in 2025.
Also read Pharmaceutical Biotechnology Industry Report 2009-2010